GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Forward Rate of Return (Yacktman) %

Rezolute (Rezolute) Forward Rate of Return (Yacktman) % : 0.00% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Rezolute Forward Rate of Return (Yacktman) %?

Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Rezolute's forward rate of return for was 0.00%.

The historical rank and industry rank for Rezolute's Forward Rate of Return (Yacktman) % or its related term are showing as below:

RZLT's Forward Rate of Return (Yacktman) % is not ranked *
in the Biotechnology industry.
Industry Median: 10.76
* Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.

Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Rezolute Forward Rate of Return (Yacktman) % Historical Data

The historical data trend for Rezolute's Forward Rate of Return (Yacktman) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rezolute Forward Rate of Return (Yacktman) % Chart

Rezolute Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Forward Rate of Return (Yacktman) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Rezolute Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Forward Rate of Return (Yacktman) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rezolute's Forward Rate of Return (Yacktman) %

For the Biotechnology subindustry, Rezolute's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rezolute's Forward Rate of Return (Yacktman) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rezolute's Forward Rate of Return (Yacktman) % distribution charts can be found below:

* The bar in red indicates where Rezolute's Forward Rate of Return (Yacktman) % falls into.



Rezolute Forward Rate of Return (Yacktman) % Calculation

Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):

If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.

The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).

Rezolute's Forward Rate of Return of Mar. 2024 is

Forward Rate of Return=Normalized Free Cash Flow/Price+5-Year EBITDA Growth Rate
=0/2.55+0
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rezolute  (NAS:RZLT) Forward Rate of Return (Yacktman) % Explanation

Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.

For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.


Be Aware

In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.


Rezolute Forward Rate of Return (Yacktman) % Related Terms

Thank you for viewing the detailed overview of Rezolute's Forward Rate of Return (Yacktman) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rezolute (Rezolute) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Forward Rate of Return (Yacktman) %
Traded in Other Exchanges
N/A
Address
275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Executives
Brian Kenneth Roberts officer: Chief Medical Officer C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Gil M Labrucherie director 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Wladimir Hogenhuis director 60 LEVERONI COURT, NOVATO CA 94949
Nerissa Kreher director C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Handok, Inc. 10 percent owner 132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Philippe Fauchet director C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim director C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc. 10 percent owner 700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller officer: VP Finance & CAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young-jin Kim director 49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Young Chul Sung director 101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola officer: Chief Financial Officer 111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp 10 percent owner 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch director C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089
Morgan Fields officer: Chief Accounting Officer 890 SANTA CRUZ AVE., MENLO PARK CA 94025